News

PMLive4h
Novo Nordisk and Septerna enter $2.2bn cardiometabolic disease partnership
Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 ...
Ozempic Maker Novo Nordisk Looks For New Chief, Jørgensen Steps Down From CEO Role
Novo Nordisk CEO steps down after pressure from shareholders. Former CEO to join board as observer. Company remains ...
Zacks.com on MSN2h
Novo Nordisk Stock Gains 14% in a Month: What Should Investors Do?
Despite competitive pressures in the obesity market, long-term investors may stay invested in NVO stock due to strong demand ...
STAT2d
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Medical Marketing & Media5h
Rx Rundown: Novo Nordisk, Pathos AI, GSK and more
Novo Nordisk announced it will work with the biotech Septerna to develop oral GLP-1 obesity drugs in a deal worth up to $2.2 ...
Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results
Announced Global Collaboration with Novo Nordisk to Develop Oral Small Molecules for Metabolic Diseases with Over $2.2 Billion in Potential Milestone Payments On Track to Select a Next-Generation Oral ...
CEO of Novo Nordisk, Maker of Weight Loss Drug Wegovy, to Step Down in Wake of Share Price Drop
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...